神経因性疼痛における大麻誘導体の概念実証試験 (CAN)
神経因性疼痛における大麻誘導体の概念実証試験。
Chronic neuropathic pain (CNP) is disabling. Research on frontline treatments for CNP, shows inconsistent outcomes and dissatisfaction among Veterans. Veterans and clinicians have shown significant interest in cannabis derivatives (THC, CBD) for neuropathic pain control, but there are no well-controlled trials guiding expectations for benefit and adverse outcomes associated with cannabis for CNP. Because Veterans are likely to present with pain and pain-related polymorbidity significantly differing from that of civilians, a well-structured clinical trial of cannabinoids for Veterans with CNP is vital.
調査の概要
詳細な説明
Chronic pain is a significant burden to United States Veterans and is a particular concern for Veterans. One of the causes of pain is chronic neuropathic pain (CNP). Frontline treatment for CNP, show inconsistent outcomes and have significant side effects. The ongoing opioid crisis has led to significant interest in safe and effective alternatives for pain control, and there is a significant need for research on desirable options for pain control that are likely to improve treatment adherence and outcomes. Veterans groups and Veterans Affairs clinicians have expressed significant interest in cannabis and its principal constituents (delta-9-tetrahydrocannabinol, THC; cannabidiol, CBD) for pain management, but the extant research describing the potential risks and benefits of cannabis for pain is weak. This randomized trial was developed as a proof of concept study to determine if cannabis constituents (THC, CBD, and THC+CBD) are superior to placebo in reducing pain in Veterans with CNP. The study is to recruit a sample of 320 adult Veterans who meet diagnostic criteria for high-impact CNP, are on stable treatment(s) for CNP, are not current cannabis users and who do not meet diagnostic criteria for Cannabis Use Disorder. This randomized phase II, 4-arm clinical trial aims to determine if cannabis constituents (THC, CBD) or their combination (THC+CBD) are superior to placebo in reducing pain in Veterans with CNP. This trial will offer the first evidence describing the potential benefits and adverse effects of cannabinoids for CNP in Veterans.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Courtney C DiCocco
- 電話番号:(203) 932-5711
- メール:Courtney.DiCocco@va.gov
研究連絡先のバックアップ
- 名前:Mohini Ranganathan, MD
- 電話番号:(203) 932-5711
- メール:Mohini.Ranganathan@va.gov
研究場所
-
-
California
-
San Diego、California、アメリカ、92161-0002
- 募集
- VA San Diego Healthcare System, San Diego, CA
-
コンタクト:
- Albert Leung, MD
- 電話番号:858-642-3029
- メール:albert.leung@va.gov
-
West Los Angeles、California、アメリカ、90073-1003
- 積極的、募集していない
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA
-
-
Connecticut
-
West Haven、Connecticut、アメリカ、06516-2770
- 募集
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT
-
主任研究者:
- Deepak D'Souza, MD MBBS
-
コンタクト:
- Deepak D'Souza, MD MBBS
- 電話番号:2594 (203) 932-5711
- メール:Deepak.DSouza@va.gov
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02908-4734
- 募集
- Providence VA Medical Center, Providence, RI
-
コンタクト:
- Jane Metrik, PhD
- 電話番号:3400 401-273-7100
- メール:jane.metrik@va.gov
-
-
Texas
-
San Antonio、Texas、アメリカ、78229-4404
- 募集
- South Texas Health Care System, San Antonio, TX
-
コンタクト:
- Muhammad Baig, MD
- 電話番号:18244 210-617-5300
- メール:muhammad.baig@va.gov
-
-
Washington
-
Seattle、Washington、アメリカ、98108-1532
- 終了しました
- VA Puget Sound Health Care System Seattle Division, Seattle, WA
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Able to provide written consent
- Veterans 21 years and older at the date of screening
- Meet diagnostic criteria for neuropathic pain as defined by the Neuropathic Pain Special Interest Group of the International Association for the Study of Pain (NeuPSIG)
- Meet criteria for persistent, high-impact pain criteria.
- Presence of allodynia confirmed by one of the screening dynamic brush tests
- women of childbearing potential who agree to abide by contraceptive requirements
Exclusion Criteria:
- Actively engaged in or planning to enter a program of non-pharmacological invasive intervention for pain at the time of enrollment
- Peripheral neuropathy is not a primary source of neuropathic pain
- Hypersensitivity to THC, CBD, or THC/CBD
- Self-report of cannabis use during screening phase confirmed by positive urine toxicology for THC-COOH as measured and resulted at visit 5 before randomization
- Unwilling to refrain from using cannabis or cannabis-based products through the entire duration of the study
- Diagnosis of DSM-5 Cannabis Use Disorder in the past 6 months
- Current DSM-5 diagnosis of cannabis use disorder, substance use disorder or serious psychiatric disorders
- Actual change or intent to change is greater than a 20% change (increase or decrease) in any other medication for pain or non-pharmacological treatment from 4 weeks before the screening appointment until completion of study (i.e., visit 13)
- Opioid doses > 400 mg MME (morphine milligram equivalent)
- Women who are pregnant or breastfeeding, or who intend to become pregnant in the 12 weeks from enrollment
- Any current unstable or concerning medical condition that would place the patient at increased risk, including hepatic, respiratory, immunological, cardiovascular, endocrine, or renal disease, or in the opinion of the investigator, prevents adherence with the protocol
- Need for immediate psychiatric hospitalization
- Enrolled in a medical marijuana program
- Federal employee
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:THC (Syndros)
Target dose of 10mg per day. |
Placebo Participants will receive a target dose of 10mg per day of THC (Syndros). |
|
アクティブコンパレータ:CBD (Epidolex)
Target dose of 800 mg per day. |
Placebo Participants will receive a target dose of 800 mg per day of CBD (Epidolex). |
|
アクティブコンパレータ:THC + CBD (Nabiximols)
Target dose of 10.8 mg / 10 mg per day. |
Placebo Participants will receive a target dose of 10.8 mg / 10 mg per day of THC + CBD (Nabiximols). |
|
プラセボコンパレーター:Placebo
Identical in appearance to the three active comparators. |
Placebo |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To compare the short-term efficacy of THC, CBD, or THC+CBD vs Placebo on Neuropathic Pain as measured by the Numeric Rating Scale of Pain
時間枠:Baseline, Week 6
|
The mean change in the weekly average of daily Numeric Rating Scale (NRS) pain score (0-10 scale; 0=no pain, 10=worst possible pain) from baseline to week 6. |
Baseline, Week 6
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To assess the efficacy of THC, CBD, or THC+CBD vs Placebo in pain quality (allodynia) as measured by the Quantitative Sensory Testing.
時間枠:Baseline, Week 2, Week 4, Week 6, Week 8
|
Allodynia measured by Quantitative Sensory Testing (QST) (0-10 scale; 0=no pain, 10=worst possible pain) |
Baseline, Week 2, Week 4, Week 6, Week 8
|
|
To assess the efficacy of THC, CBD, or THC+CBD vs Placebo in disability and function as measured by the Neuropathic Pain Scale.
時間枠:Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
|
Neuropathic Pain Scale (NPS) total score; 7 different questions/sensations (for each individual item 0-10 scale; 0= not present/no pain, 10= most sensation). Individual scores analyzed separately for pain quality and mean score analyzed for overall neuropathic pain). |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
|
|
To assess the efficacy of THC, CBD, or THC+CBD vs Placebo in disability and function as measured by the Gait Speed Test
時間枠:Baseline, Week 4, Week 8
|
Distance walked (meters)/time (seconds) measured by Gait Speed Test (lower score = worse, higher score =better) |
Baseline, Week 4, Week 8
|
|
To assess the efficacy of THC, CBD, or THC+CBD vs Placebo in mean changes in perceived improvement as measured by the Patient Global Impression of Change
時間枠:Baseline, Week 2, Week 4, Week 6, Week 8
|
Patient Global Impression of Change (PGIC) 1-7 point ordinal scale assessed (1 = worse, 7 = better) |
Baseline, Week 2, Week 4, Week 6, Week 8
|
|
To assess the efficacy of THC, CBD, or THC+CBD vs Placebo in mean changes in perceived improvement as measured by the patient satisfaction visual analog scale.
時間枠:Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
|
Patient satisfaction with intervention on visual analog scale (VAS, 0-100, 0=no satisfaction, 100 = complete satisfaction). |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
|
|
To assess the efficacy of THC, CBD, or THC+CBD vs Placebo in mean changes in quality of life measured by the Veterans RAND 12 Item Health Survey
時間枠:Baseline, Week 4, Week 8
|
Mental Component Score (MCS) and Physical Component Score (PCS) measured by Veterans RAND 12 Item Health Survey (VR-12). VR-12 is an algorithmic score with ranges from 0-100 (0 indicates worse health-related quality of life and 100 represents better health-related quality of life). |
Baseline, Week 4, Week 8
|
|
To assess the efficacy of THC, CBD, or THC+CBD vs Placebo in anxiety measured by the Generalized Anxiety Disorder-7.
時間枠:Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
|
Generalized anxiety symptomology is measured by Generalized Anxiety Disorder-7 (GAD-7) total score. (total score ranges from 0-21; Score 0-4 = minimal anxiety, Score 5-9 = mild anxiety, Score 10-14 = moderate anxiety, Score 15-21 = severe anxiety) |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
|
|
To assess the efficacy of THC, CBD, or THC+CBD vs Placebo in pain quality as measured by the Short Form McGill Pain Questionnaire (SF-MPQ-2).
時間枠:Baseline, Week 2, Week 4, Week 6, Week 8
|
Short Form McGill Pain Questionnaire (SF-MPQ-2) total score and four subscales (continuous pain, intermittent pain, predominantly neuropathic pain, affective). (0= no pain to 5= excruciating pain) |
Baseline, Week 2, Week 4, Week 6, Week 8
|
|
To assess the efficacy of THC, CBD, or THC+CBD vs Placebo in mean changes in disability and function as measured by the Brief Pain Inventory-Diabetic Peripheral Neuropathy.
時間枠:Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
|
Brief Pain Inventory-Diabetic Peripheral Neuropathy (BPI-DPN) pain intensity score (first four items 0-10; 10= pain as bad as can imagine) (remaining items 0% (no relief)-100% (complete relief)) and pain interference score (0-10, 10= completely intense). |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
|
|
To assess the efficacy of THC, CBD, or THC+CBD vs Placebo in emotional functioning (severity of depression) as measured by the Patient Health Questionnaire-9.
時間枠:Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
|
Severity of depression is measured by Patient Health Questionnaire-9 (PHQ-9) total score (0-27; 0=none, 27=worst). |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
|
|
To assess the efficacy of THC, CBD, or THC+CBD vs Placebo in emotional functioning (PTSD symptoms) as measured by the PTSD Checklist-DSM-5 (PCL-5).
時間枠:Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
|
PTSD symptoms are assessed by PTSD Checklist-DSM-5 (PCL-5) total score symptom severity score (0-80; 0= not at all to 80= worst). |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
|
協力者と研究者
捜査官
- 主任研究者:Deepak D'Souza, MD MBBS、VA Connecticut Healthcare System West Haven Campus, West Haven, CT
- 主任研究者:Donald McGeary, PhD、South Texas Health Care System, San Antonio, TX
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- NURP-002-20F
- 1I01CX002378-01 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。